omitir hasta el contenido
Long-Term Consequences of Drugs on the Paediatric Cardiovascular System
CerrarVer este material de antemano
Chequeando…

Long-Term Consequences of Drugs on the Paediatric Cardiovascular System

Autor: Elizabeth HausnerMonica FiszmanJoseph HanigPatricia HarlowGwen ZornbergTodos autores
Editorial: Adis International Limited
Edición/Formato: Artículo Artículo : Inglés (eng)
Publicación:Drug Safety, 31, no. 12 (2008): 1083-1096
Base de datos:ArticleFirst
Otras bases de datos: MEDLINEElsevierBritish Library Serials
Calificación:

(todavía no calificado) 0 con reseñas - Ser el primero.

Más materiales como éste

 

&AllPage.SpinnerRetrieving;

Encontrar un ejemplar en la biblioteca

&AllPage.SpinnerRetrieving; Encontrando bibliotecas que tienen este material…

Detalles

Tipo de documento: Artículo
Todos autores / colaboradores: Elizabeth Hausner; Monica Fiszman; Joseph Hanig; Patricia Harlow; Gwen Zornberg; Solomon Sobel
ISSN:0114-5916
Nota del idioma: English
Identificador único: 365863444
Premios:

Reseñas

Reseñas contribuidas por usuarios
Recuperando reseñas de GoodReads…
Recuperando reseñas de DOGObooks…

Etiquetas

Todas las etiquetas de usuarios (1)

Ver etiquetas más populares como: lista de etiquetas | nube de etiquetas

  • good  (por 1 persona)

Materiales similares

Listas de usuarios con este material (1)

Confirmar este pedido

Ya ha pedido este material. Escoja OK si desea procesar el pedido de todos modos.

Datos enlazados


<http://www.worldcat.org/oclc/365863444>
library:oclcnum"365863444"
owl:sameAs<info:oclcnum/365863444>
rdf:typeschema:Article
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:creator
schema:datePublished"2008-12-11"
schema:description"Many pharmacological and toxicological actions of drugs in children cannot be fully predicted from adult clinical experience or from standard non-clinical toxicology studies. Numerous drugs have direct or indirect pharmacological effects on the heart and are prescribed for children of all ages. Toxicity or secondary effects may be immediate or delayed for years after drug exposure has ceased. Originally, the aim of this review was to compile information on the effect of specific drugs on the post-natal development of the cardiovascular system and to examine long-term follow-up of the use of cardio-active drugs in children. The limited database of published information caused the original question to evolve into an examination of the medical literature for three areas of information: (i) whether vulnerable developmental windows have been identified that reflect the substantial functional development that the cardiovascular system undergoes after birth; (ii) what is known about pharmacological perturbation of development; and (iii) what the likelihood is of drug exposure during childhood. We examined different scenarios for exposure including random, isolated exposure, conditions historically associated with adults, primary or secondary cardiac disease, psychiatric and neurological conditions, asthma, cancer and HIV. Except for random, isolated drug exposures, each category of possible exposure contained numerous drugs known to have either primary or secondary effects on the cardiovascular system or to influence factors associated with atherosclerosis. It is likely that a significant number of children will be prescribed drugs having either direct or indirect effects upon the immature cardiovascular system. A confounding factor is the simultaneous use of over-the-counter medications and herbal or nutraceutical preparations that a patient, parent or guardian does not mention to a prescribing physician. Metabolism is also important in assessing drug effects in children. Differences in body water : body fat ratio, age-related gastrointestinal absorption, distribution, excretion, renal function and drug metabolizing capabilities make it possible for children to have a different metabolite profile for a drug compared with adults. There is little examination of drug effects on the interdependent processes of cardiac maturation and less examination of metabolite effects. It is difficult to identify delayed toxicities in children as these adverse events may take years to manifest with many patients lost to follow-up. Clearly this is an area of study where intermediate endpoints and surrogate markers would be of great benefit. Pharmacogenomics may be useful in providing markers of increased risk or susceptibility. A perspective must be kept in balancing the possibility of a problem with the very real benefits that many children experience from the use of these pharmaceuticals."
schema:exampleOfWork<http://worldcat.org/entity/work/id/159255745>
schema:inLanguage"en"
schema:isPartOf
schema:name"Long-Term Consequences of Drugs on the Paediatric Cardiovascular System"
schema:pageStart"1083"
schema:publisher
schema:url

Content-negotiable representations

Cerrar ventana

Inicie una sesión con WorldCat 

¿No tienes una cuenta? Puede fácilmente crear una cuenta gratuita.